<div class="white-sheet">
	<div class="content-slide">


		<div class="title-bar red"></div>

		<div class="wrapper slide-2-8-2-1">


			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>
			</div>

			<div class="slide-title red two-line">
				Management of refractory aplastic anaemia: <br />the UK experience
			</div>


			<div class="content-container">

				<img class="center-img" src="media/images/slide_2-8-2-1/picture1.png" alt="" style="margin-top:60px">

			</div>

		</div>


		<div class="information-overlay overlay">

			<header>Management of refractory aplastic anaemia: the UK experience</header>
				
			<ul>
				<li><span>Physicians should consider referring patients with refractory aplastic anaemia to a specialist centre (with expertise in management of the disease) to:</span>
					<ul>
						<li><span>Reassess the patient to confirm the diagnosis of aplastic anaemia</span></li>
						<li><span>Gain access to advanced molecular testing techniques that may assist diagnoses of exclusion</span></li>
						<li><span>Provide patients with the opportunity to discuss the pros and cons of different treatment options available for refractory aplastic anaemia</span></li>
					</ul>
				</li>
				<li><span>Most treatment options for refractory aplastic anaemia are considered experimental, so enrolment into a clinical trial should also be considered</span></li>
			</ul>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/BolonB-2012-ToxicolPathol-v40p216.pdf"><span>Marsh JCW & Kulasekaraj AG. <i>Blood</i> 2013;122:3561</span></li>
			</ul>

		</div>


		

	</div>
</div>